Meitheal Pharmaceuticals says FDA approves high-concentration YUSIMRY formulation
The FDA approved a high-concentration formulation of YUSIMRY, an interchangeable biosimilar to Humira, for nine indications. Meitheal said the approval lets it offer YUSIMRY in both low- and high-concentration formulations.